Berlin Cures GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://berlincures.de
To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
Phase 2
Completed
- Conditions
- Long Covid
- Interventions
- Drug: BC 007 or matching placebo
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Berlin Cures GmbH
- Target Recruit Count
- 119
- Registration Number
- NCT05911009
- Locations
- 🇦🇹
Klinik Favoriten - Wiener Gesundheitsverbund, Vienna, Austria
🇩🇪Universitätsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany
🇪🇸Hospitalario Universitario Quironsalud Madrid, Madrid, Spain
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor
Phase 2
Completed
- Conditions
- Cardiomyopathy, DilatedAutoantibodiesHeart Failure
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Berlin Cures GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT04192214
- Locations
- 🇷🇸
Zvezdara Clinical and Hospital Centre, Belgrade, Serbia
🇷🇸Bežanijska Kosa Clinical and Hospital Centre, Belgrad, Serbia
🇷🇸Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Berlin Cures GmbH
- Target Recruit Count
- 74
- Registration Number
- NCT02955420
- Locations
- 🇩🇪
PAREXEL International GmbH, Early Phase Clinical Unit Berlin, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath